Ipatasertib Global Market Report 2026

Ipatasertib is an oral, small-molecule inhibitor that selectively targets protein kinase B (AKT), a key protein in the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway often hyperactive in cancer cells. It functions by blocking AKT and interfering with cancer cell growth, survival, and proliferation, thereby slowing tumor progression and boosting the efficacy of other treatments.

Ipatasertib's primary indications include prostate cancer, breast cancer, and additional conditions. Prostate cancer originates in the prostate, a small gland in males that produces seminal fluid. It comes in dosage forms like tablets, capsules, and more, delivered via oral or intravenous administration. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs are affecting the ipatasertib market by increasing costs of imported active pharmaceutical ingredients, specialized chemical intermediates, and oncology-grade manufacturing inputs. North America and Europe are most impacted due to reliance on cross-border pharmaceutical supply chains, while Asia-Pacific faces higher export-related production costs. These tariffs are contributing to elevated development and commercialization expenses. However, they are also supporting domestic API manufacturing, regional formulation capabilities, and long-term supply chain resilience for targeted oncology drugs.

The ipatasertib market research report is one of a series of new reports from The Business Research Company that provides ipatasertib market statistics, including ipatasertib industry global market size, regional shares, competitors with a ipatasertib market share, detailed ipatasertib market segments, market trends and opportunities, and any further data you may need to thrive in the ipatasertib industry. This ipatasertib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ipatasertib market size has grown rapidly in recent years. It will grow from $0.86 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to advancements in pi3k/akt pathway research, increasing prevalence of advanced-stage cancers, growth of targeted oncology drug pipelines, expansion of clinical trials for small-molecule inhibitors, rising adoption of precision oncology approaches.

The ipatasertib market size is expected to see rapid growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted cancer drugs, rising demand for personalized cancer therapies, expansion of combination therapy strategies, growing investments in oncology R&D, increasing focus on resistant cancer treatment options. Major trends in the forecast period include increasing focus on akt pathway inhibition therapies, rising use of combination cancer treatment regimens, growing emphasis on biomarker-driven oncology drugs, expansion of targeted small-molecule pipelines, enhanced clinical evaluation of precision oncology agents.

The rising incidence of cancer is anticipated to fuel the expansion of the ipatasertib market in the future. Cancer encompasses a range of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells throughout the body. This surge in cancer cases stems from lifestyle factors like unhealthy eating, tobacco use, lack of exercise, and heavy alcohol intake. Ipatasertib bolsters cancer therapies by inhibiting the PI3K/AKT signaling pathway, which effectively curbs tumor growth and spread. It diminishes cancer cell viability and therapeutic resistance, leading to better treatment results and patient outcomes. For instance, in April 2024, data from the American Cancer Society (ACS) and the International Agency for Research on Cancer (IARC) revealed 20 million new cancer diagnoses in 2022-higher than prior estimates-with forecasts predicting 35 million cases by 2050, a 77% rise. Thus, the growing prevalence of cancer is propelling the ipatasertib market forward.

The escalating healthcare spending is anticipated to fuel the expansion of the ipatasertib market in the future. Healthcare expenditure encompasses the overall funds allocated to medical services, treatments, infrastructure, research, and public health efforts aimed at sustaining or enhancing health results. This surge in healthcare spending stems from the growing incidence of chronic illnesses, which demand prolonged and expensive therapies. Elevated healthcare expenditure bolsters ipatasertib's progress by supplying greater financial support and resources for research and clinical studies, facilitating the advancement of cutting-edge cancer treatments. It speeds up drug development processes and promotes wider availability of precision therapies, leading to better patient results and therapeutic effectiveness. For instance, in May 2024, the Office for National Statistics-a UK government agency-reported that total healthcare spending rose by 5.6% in nominal terms during 2023, marking a 0.9% uptick from 2022. Thus, the increasing healthcare expenditure is propelling the ipatasertib market's growth.

The growing demand for personalized medicine is poised to accelerate the ipatasertib market's expansion. Personalized medicine involves customizing treatment and prevention plans based on a person's distinct genetic profile, lifestyle, and surroundings. Its rising popularity stems mainly from progress in genomics, which allows for accurate detection of genetic differences and individualized therapies. Ipatasertib supports personalized medicine by focusing on the PI3K/AKT signaling pathway, enabling cancer therapies that align closely with a patient's specific tumor characteristics. This approach boosts treatment success by targeting precise genetic and molecular features, minimizing resistance, and enhancing results for patients. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit, reported that the FDA approved 26 new personalized medicines in 2023-up notably from the 12 in 2022. Thus, the increasing embrace of personalized medicine is fueling ipatasertib market growth.

Major companies operating in the ipatasertib market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation

North America was the largest region in the ipatasertib market in 2025. The regions covered in the ipatasertib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ipatasertib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ipatasertib market consists of sales of capivasertib (AZD5363), perifosine, afuresertib (GSK2110183), MK-2206, and taselisib (GDC-0032). Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ipatasertib Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ipatasertib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ipatasertib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ipatasertib market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Prostate Cancer; Breast Cancer; Other Cancers
• 2) By Dosage Form: Tablets; Capsules; Other Dosages
• 3) By Route Of Administration: Oral; Intravenous
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Prostate Cancer: Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Non-Metastatic Prostate Cancer
• 2) By Breast Cancer: Triple-Negative Breast Cancer (TNBC); Hormone Receptor-Positive Or Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer; Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
• 3) By Other Cancers: Ovarian Cancer; Gastric Cancer; Pancreatic Cancer; Colorectal Cancer; Lung Cancer
• Companies Mentioned: Thermo Fisher Scientific Inc.; Illumina Inc.; Myriad Genetics Inc.; BGI Genomics Co. Ltd.; Invitae Corporation; Guardant Health Inc.; GeneDx LLC; Ancestry Inc.; Oxford Nanopore Technologies plc; Genomic Health Inc.; 23andMe Holding Co.; Color Health Inc.; Helix OpCo LLC; Personalis Inc.; Dante Genomics; Gene By Gene Ltd.; Veritas Genetics Inc.; Futura Genetics; Nebula Genomics Inc.; Pathway Genomics Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.